New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-d...
Main Authors: | Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Diabetes Association
2022-07-01
|
Series: | Diabetes & Metabolism Journal |
Subjects: | |
Online Access: | http://e-dmj.org/upload/pdf/dmj-2022-0198.pdf |
Similar Items
-
Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications
by: Amalia Despoina Koutsogianni, et al.
Published: (2023-05-01) -
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
by: Joon Ho Moon, et al.
Published: (2022-08-01) -
Lipoprotein(a)—60 Years Later—What Do We Know?
by: Anna Pasławska, et al.
Published: (2023-10-01) -
Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
by: Konstantinos Koskinas, et al.
Published: (2016-07-01) -
Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients
by: Ulrich Julius
Published: (2018-05-01)